seractil 1016x130

A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis

Diagnosis and Management of Paget’s Disease of Bone in Adults: A Clinical Guideline

The effects of denosumab and alendronate on osteoporosis in hemodialysis patients

Exercise for preventing falls in older people living in the community

A novel interplay between irisin & PTH: from basic studies to clinical evidence in hyperparathyroidism

Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab for up to 10 Years

Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B

Is It Time to Stop (or Pause) Vertebral Augmentation?

The Efficacy & Safety of Vertebral Augmentation: Second ASBMR Task Force Report

GOOD NEWS FOR ROMOSOZUMAB

An FDA advisory panel on Wednesday voted 18-1 that the benefits of Amgen and UCB's monthly injection Evenity (romosozumab) outweigh its risks for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

Serum 25-hydroxyvitamin D status, quantitative ultrasound parameters, and their determinants in Greek population

ΑΡΘΡΟ: ΜΕΤΑ-ΑΝΑΛΥΣΗ & ΒΙΤΑΜΙΝΗ D

FRAX:Greek intervention thresholds

ΑΡΘΡΟ: ΖΟΛΕΔΡΟΝΙΚΟ ΟΞΥ & ΟΣΤΕΟΠΕΝΙΑ

Management of Chronic Kidney Disease